Comprehensive Dermatologic Drug Therapy
Description:
Safely and effectively prescribe today's full spectrum of topical, intralesional, and systemic drugs for dermatologic disorders! Dr. Steven E. Wolverton and a team of leading international experts explain what drugs to use, when to use them...and what to watch out for. This invaluable quick reference tool provides full-text explanations as well as at-a-glance summaries of key pharmacologic information, as well as treatment protocols and associated costs.
- Provides at-a-glance access to key information including summaries of indications/contraindications, dosage guidelines, drug interactions, drug monitoring guidelines, adverse effects, and treatment protocols.
- Features a consistent organization throughout to expedite fast reference.
- Provides purchase information for major drugs, to help you and your patients.
- Includes a highly detailed, disease-specific index, helping you to evaluate drug options for each disease discussed.
- Includes handheld software for on-the-go reference.
- Highlights key controversies and provides expert guidance in a Question and Answer feature.
- Presents new chapters on TNF Inhibitors, Signal II Cytokine Inhibitors, Pimicrolimus, IV Immunoglobulin, Drug-Induced Malignancies, Polymorphisms, and non-dermatologic drugs related to dermatologic problems.
- Features updates on new drug findings and new research, especially findings on predicting an individual response to drugs on the basis of ethnicity and gender.
Best prices to buy, sell, or rent ISBN 9781416024712
Frequently Asked Questions about Comprehensive Dermatologic Drug Therapy
If you’re interested in selling back the Comprehensive Dermatologic Drug Therapy book, you can always look up BookScouter for the best deal. BookScouter checks 30+ buyback vendors with a single search and gives you actual information on buyback pricing instantly.
As for the Comprehensive Dermatologic Drug Therapy book, the best buyback offer comes from and is $ for the book in good condition.
Not enough insights yet.
Not enough insights yet.